Akorn has received its second warning letter from the US Food and Drug Administration in the span of six months. This warning letter was regarding the inspection that took place from 23 July to 30 August 2018 at Akorn’s Somerset, New Jersey facility.
An Akorn spokesperson told Generics Bulletin that the company “takes the FDA warning letter seriously and is working diligently to...





